As African nations begin to ease lockdown restrictions, health systems are bracing to prevent the novel coronavirus from spreading rapidly through their populations.
Coronavirus Disease 2019 (COVID-19)
The scale and speed of the global vaccine research and development effort in response to COVID-19 is unprecedented.
During the COVID-19 pandemic, we have become acutely aware of how precious time is and the potential repercussions of delays or inefficiencies.
Antimicrobial resistance (AMR) is a global health challenge which can undermine standard treatments and procedures on which we have come to rely.
For nearly 200 years, USP’s public standards have served to establish a common foundation upon which the quality of medicines can be evaluated, building trust in the healthcare system and enabling innovation to thrive. During that time, medicine has evolved tremendously.
I was pleased to address the American Association of Pharmaceutical Scientists (AAPS) on May 12 during a webinar focused on the impact of the COVID-19 pandemic on the supply of quality medicines.
As the impact of the COVID-19 pandemic continues to unfold, each day brings to light new realizations of just how interconnected, and sometimes vulnerable, the global supply chain for medicines is.